HFBK Stock | News | Quote | Stock Forum | Wednesday, October

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Harford Bank of Aberdeen HFBK Company Overview 

Harford Bank of Aberdeen HFBK Current Price and Quotes
Last Price 22.25
Previous Close 21.99 Open 22.25
Daily Range 22.25 - 22.25 52wk Range 24.00 - 14.30
Volume 161 Dividend 0.60
Average Vol (3m) 609 Yield 2.6966

HFBK Stock Message Board http://investorshangout.com/search?q=HFBK&...mp;yt1=Go!

Last Updated: Wednesday, October 30, 2013 02:28:43 AM

Harford Bank of Aberdeen HFBK
Company Information

8 W. Bel Air Ave.
P.O. Box 640
Aberdeen, MD 21001

Website: http://www.harfordbank.com
Phone: 410-272-5000

Harford Bank of Aberdeen HFBK
Harford Bank of Aberdeen HFBK
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: Bank/Thrift
Audited Financials Audited
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 6022 - State commercial banks
Incorporated In: MD, USA
Year of Inc. 1964
Employees 64 a/o Sep 30, 2006
Company Officers/Contacts

Charles H. Jacobs Jr. President, CEO
Charlotte A. Mock EVP, CFO
Donald Young Senior VP
Company Directors

Not Available
Company Notes

Formerly=Harford National Bank (Aberdeen, MD) until 9-01
Service Providers

Auditor/Accountant
Rowles & Company, LLP
101 East Chesapeake Avenue
Suite 300
Baltimore, MD, 21286
United States

Legal Counsel
Not Available
Investor Relations Firm
Not Available

Harford Bank of Aberdeen HFBK
HFBK Security Details

Share Structure

Market Value1 $24,920,423 a/o Oct 29, 2013
Shares Outstanding 1,120,019 a/o Dec 05, 2012
Float Not Available
Authorized Shares 5,000,000 a/o Nov 29, 2006
Par Value  10
Shareholders

Shareholders of Record Not Available
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.15) Oct 02, 2013 Oct 04, 2013 Oct 25, 2013
Dividend (0.15) Jul 02, 2013 Jul 05, 2013 Jul 26, 2013
Dividend (0.15) Apr 03, 2013 Apr 05, 2013 Apr 26, 2013
Security Notes

Capital Change=shs increased by 3 for 2 split. Ex-date=12-30-97. Rec-date=12-5-97. Pay-date=12-26-97.
Capital Change=Stk. Div. =20%. Ex-date=12-02-98. Rec. Date=12-04-98. Pay. date=12-25-98.
Cap. Change=Stk. Div.=5%. Ex-date=12-12-00. Rec. date=12-01-00. Pay. date=12-22-00.
Capital Change=Stk. Div.=3%. Ex-date=11/30/2005. Rec date=12/02/2005. Pay date=12/23/2005.
Capital Change=Stk. Div.=3%. Ex-date=12/01/2004. Rec date=12/03/2004. Pay date=12/24/2004.
Capital Change=Stk. Div.=3%. Ex-date=12/11/2001. Rec date=12/07/2001. Pay date=12/28/2001.
Capital Change=Stk. Div.=3%. Ex-date=12/05/2002. Rec date=12/06/2002. Pay date=12/27/2002.
Capital Change=Stk. Div.=3%. Ex-date=12/03/2003. Rec date=12/05/2003. Pay date=12/26/2003.
Capital Change=Stk. Div.=20%. Ex-date=11/29/2006. Rec date=12/01/2006. Pay date=12/22/2006.
Capital Change=Stk. Div.=3% Ex-date=12/05/2007. Rec date=12/07/2007. Pay date=12/28/2007.
Capital Change=Stk. Div.=3% Ex-date=12/03/2008. Rec date=12/05/2008. Pay date=12/26/2008.
Capital Change=Stk. Div.=3% Ex-date=12/02/2009. Rec date=12/04/2009. Pay date=12/25/2009.
Capital Change=Stk. Div.=3% Ex-date=12/01/2010. Rec date=12/03/2010. Pay date=12/24/2010.
Capital Change=Stk. Div.=3% Ex-date=11/30/2011. Rec date=12/02/2011. Pay date=12/23/2011.
Capital Change=shs increased by 1.03 for 1 split. Ex-date=12/05/2012. Rec date=12/07/2012. Pay date=12/28/2012.
Short Selling Data

Short Interest 0 (-100%)
Jul 15, 2013
Significant Failures to Deliver  No
Transfer Agent(s)



Harford Bank of Aberdeen HFBK Financials
HFBK


Harford Bank of Aberdeen HFBK Recent News

HFBK Harford Bank of Aberdeen Research DD Guide

Stock Message Board http://investorshangout.com/search?q=HFBK&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/HFBK/quote
Stock Chart http://www.otcmarkets.com/stock/HFBK/chart
Company Info http://www.otcmarkets.com/stock/HFBK/company-info
Recent News http://www.otcmarkets.com/stock/HFBK/news
Financials http://www.otcmarkets.com/stock/HFBK/financials
Filings and Disclosure http://www.otcmarkets.com/stock/HFBK/filings
Short Sales http://www.otcmarkets.com/stock/HFBK/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/HFBK/insider-transactions
Research Reports http://www.otcmarkets.com/stock/HFBK/research
Summary http://finance.yahoo.com/q?s=HFBK
Historical Prices http://finance.yahoo.com/q/hp?s=HFBK+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=HFBK
Basic Chart http://finance.yahoo.com/q/bc?s=HFBK+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=HFBK+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=HFBK+Headlines
Press Releases http://finance.yahoo.com/q/p?s=HFBK+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=HFBK+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=HFBK+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=HFBK+Industry
Major Holders http://finance.yahoo.com/q/mh?s=HFBK+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=HFBK+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=HFBK+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=HFBK
Balance Sheet http://finance.yahoo.com/q/bs?s=HFBK
Cash Flow http://finance.yahoo.com/q/cf?s=HFBK+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/HFBK
Market Watch http://www.marketwatch.com/investing/stock/HFBK
Bloomberg http://www.bloomberg.com/quote/HFBK:US
Morningstar http://quotes.morningstar.com/stock/s?t=HFBK
Bussinessweek http://investing.businessweek.com/research/st...icker=HFBK
Barchart http://www.barchart.com/quotes/stocks/HFBK
OTC Short Report http://otcshortreport.com/index.php?index=HFBK
Investopedia http://www.investopedia.com/markets/stocks/HFBK/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading